Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2008

01.09.2008 | Preclinical Study

Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer

verfasst von: Mary A. Bewick, Michael S. C. Conlon, Robert M. Lafrenie

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Treatments for metastatic breast cancer (MBC) are primarily palliative with variable efficacy and outcomes may be influenced by individual differences in drug metabolism. In this study, we examined the association of single nucleotide polymorphisms (SNPs) in genes involved in drug metabolism with progression free survival (PFS) and breast cancer specific survival (BCSS) in 95 patients with MBC that received high dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT). SNPs in the SOD2 (SOD2-01, Val16Ala), MPO (MPO-02, -463 promoter variant) and GSTP1 [GSTP1-01 (Ile105Val), GSTP1-02 (Ala114Val)] genes were examined in DNA isolated from cryopreserved blood products using genotyping assays. Survival was analysed using Cox proportional hazard models and Kaplan–Meier estimates. Patients with the SOD2-01 (TT) genotype had increased risk of disease progression [hazard ratio (HR): 2.52; 95% confidence interval (CI), 1.31–4.85] and breast cancer specific death (HR: 1.92; 95% CI: 1.03–3.57). Risks were increased for patients with both SOD2-01 (TT) and GSTP1-01 (GG or AG) genotypes (HR for disease progression: 2.57, 95% CI: 1.32–5.00 and HR for breast cancer specific death: 2.27; 95% CI: 1.18–4.34). In multivariable analysis, the combined genotype group of SOD2-01 and GSTP1-01 was an independent predictor of PFS and BCSS. HRs progressively increased with increasing number of genotypes associated with worse survival, with p (trend) of 0.005 and 0.006 for PFS and BCSS, respectively. These results suggest that SNPs in genes involved in drug metabolism may influence survival outcome for patients with MBC receiving HDC and ASCT.
Literatur
1.
Zurück zum Zitat Hayes JD, Strange RC (2000) Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 61:154–166PubMedCrossRef Hayes JD, Strange RC (2000) Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 61:154–166PubMedCrossRef
2.
Zurück zum Zitat Liu G, Zhou W, Wang LI, Park S, Miller DP, Xu LL, Wain JC, Lynch TJ, Su L, Christiani DC (2004) MPO and SOD2 polymorphisms, gender, and the risk of non-small cell lung carcinoma. Cancer Lett 214:69–79PubMedCrossRef Liu G, Zhou W, Wang LI, Park S, Miller DP, Xu LL, Wain JC, Lynch TJ, Su L, Christiani DC (2004) MPO and SOD2 polymorphisms, gender, and the risk of non-small cell lung carcinoma. Cancer Lett 214:69–79PubMedCrossRef
3.
Zurück zum Zitat Olson SH, Carlson MD, Ostrer H, Harlap S, Stone A, Winters M, Ambrosone CB (2004) Genetic variants in SOD2, MPO, and NQO1, and risk of ovarian cancer. Gynecol Oncol 93:615–620PubMedCrossRef Olson SH, Carlson MD, Ostrer H, Harlap S, Stone A, Winters M, Ambrosone CB (2004) Genetic variants in SOD2, MPO, and NQO1, and risk of ovarian cancer. Gynecol Oncol 93:615–620PubMedCrossRef
4.
Zurück zum Zitat Yang G, Shu XO, Ruan ZX, Cai QY, Jin F, Gao YT, Zheng W (2005) Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma. Cancer 103:52–58PubMedCrossRef Yang G, Shu XO, Ruan ZX, Cai QY, Jin F, Gao YT, Zheng W (2005) Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma. Cancer 103:52–58PubMedCrossRef
5.
Zurück zum Zitat Ambrosone CB, Ahn J, Singh KK, Rezaishiraz H, Furberg H, Sweeney C, Coles B, Trovato A (2005) Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer. Cancer Res 65:1105–1111PubMed Ambrosone CB, Ahn J, Singh KK, Rezaishiraz H, Furberg H, Sweeney C, Coles B, Trovato A (2005) Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer. Cancer Res 65:1105–1111PubMed
6.
Zurück zum Zitat Beeghly A, Katsaros D, Chen H, Fracchioli S, Zhang Y, Massobrio M, Risch H, Jones B, Yu H (2006) Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol Oncol 100:330–337PubMedCrossRef Beeghly A, Katsaros D, Chen H, Fracchioli S, Zhang Y, Massobrio M, Risch H, Jones B, Yu H (2006) Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol Oncol 100:330–337PubMedCrossRef
7.
Zurück zum Zitat Conklin KA (2004) Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther 3:294–300PubMedCrossRef Conklin KA (2004) Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther 3:294–300PubMedCrossRef
8.
Zurück zum Zitat Weijl NI, Cleton FJ, Osanto S (1997) Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treat Rev 23:209–240PubMedCrossRef Weijl NI, Cleton FJ, Osanto S (1997) Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treat Rev 23:209–240PubMedCrossRef
9.
Zurück zum Zitat La TF, Orlando A, Silipigni A, Giacobello T, Pergolizzi S, Aragona M (1997) Increase of oxygen free radicals and their derivatives in chemo- and radiation treated neoplasm patients. Minerva Med 88:121–126 La TF, Orlando A, Silipigni A, Giacobello T, Pergolizzi S, Aragona M (1997) Increase of oxygen free radicals and their derivatives in chemo- and radiation treated neoplasm patients. Minerva Med 88:121–126
10.
Zurück zum Zitat Lopez-Lazaro M (2006) Dual role of hydrogen peroxide in cancer: possible relevance to cancer chemoprevention and therapy. Cancer Lett 252:1–8PubMedCrossRef Lopez-Lazaro M (2006) Dual role of hydrogen peroxide in cancer: possible relevance to cancer chemoprevention and therapy. Cancer Lett 252:1–8PubMedCrossRef
11.
Zurück zum Zitat Alexandre J, Batteux F, Nicco C, Chereau C, Laurent A, Guillevin L, Weill B, Goldwasser F (2006) Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int J Cancer 119:41–48PubMedCrossRef Alexandre J, Batteux F, Nicco C, Chereau C, Laurent A, Guillevin L, Weill B, Goldwasser F (2006) Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int J Cancer 119:41–48PubMedCrossRef
12.
Zurück zum Zitat Ramanathan B, Jan KY, Chen CH, Hour TC, Yu HJ, Pu YS (2005) Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 65:8455–8460PubMedCrossRef Ramanathan B, Jan KY, Chen CH, Hour TC, Yu HJ, Pu YS (2005) Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 65:8455–8460PubMedCrossRef
13.
Zurück zum Zitat Sutton A, Imbert A, Igoudjil A, Descatoire V, Cazanave S, Pessayre D, Degoul F (2005) The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability. Pharmacogenet Genomics 15:311–319PubMedCrossRef Sutton A, Imbert A, Igoudjil A, Descatoire V, Cazanave S, Pessayre D, Degoul F (2005) The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability. Pharmacogenet Genomics 15:311–319PubMedCrossRef
14.
Zurück zum Zitat Ambrosone CB, Freudenheim JL, Thompson PA, Bowman E, Vena JE, Marshall JR, Graham S, Laughlin R, Nemoto T, Shields PG (1999) Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer. Cancer Res 59:602–606PubMed Ambrosone CB, Freudenheim JL, Thompson PA, Bowman E, Vena JE, Marshall JR, Graham S, Laughlin R, Nemoto T, Shields PG (1999) Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer. Cancer Res 59:602–606PubMed
15.
Zurück zum Zitat Mitrunen K, Sillanpaa P, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Uusitupa M, Hirvonen A (2001) Association between manganese superoxide dismutase (MnSOD) gene polymorphism and breast cancer risk. Carcinogenesis 22:827–829PubMedCrossRef Mitrunen K, Sillanpaa P, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Uusitupa M, Hirvonen A (2001) Association between manganese superoxide dismutase (MnSOD) gene polymorphism and breast cancer risk. Carcinogenesis 22:827–829PubMedCrossRef
16.
Zurück zum Zitat Stoehlmacher J, Ingles SA, Park DJ, Zhang W, Lenz HJ (2002) The -9Ala/-9Val polymorphism in the mitochondrial targeting sequence of the manganese superoxide dismutase gene (MnSOD) is associated with age among Hispanics with colorectal carcinoma. Oncol Rep 9:235–238PubMed Stoehlmacher J, Ingles SA, Park DJ, Zhang W, Lenz HJ (2002) The -9Ala/-9Val polymorphism in the mitochondrial targeting sequence of the manganese superoxide dismutase gene (MnSOD) is associated with age among Hispanics with colorectal carcinoma. Oncol Rep 9:235–238PubMed
17.
Zurück zum Zitat Woodson K, Tangrea JA, Lehman TA, Modali R, Taylor KM, Snyder K, Taylor PR, Virtamo J, Albanes D (2003) Manganese superoxide dismutase (MnSOD) polymorphism, alpha-tocopherol supplementation and prostate cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study (Finland). Cancer Causes Control 14:513–518PubMedCrossRef Woodson K, Tangrea JA, Lehman TA, Modali R, Taylor KM, Snyder K, Taylor PR, Virtamo J, Albanes D (2003) Manganese superoxide dismutase (MnSOD) polymorphism, alpha-tocopherol supplementation and prostate cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study (Finland). Cancer Causes Control 14:513–518PubMedCrossRef
18.
Zurück zum Zitat Hung RJ, Boffetta P, Brennan P, Malaveille C, Gelatti U, Placidi D, Carta A, Hautefeuille A, Porru S (2004) Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk. Carcinogenesis 25:973–978PubMedCrossRef Hung RJ, Boffetta P, Brennan P, Malaveille C, Gelatti U, Placidi D, Carta A, Hautefeuille A, Porru S (2004) Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk. Carcinogenesis 25:973–978PubMedCrossRef
19.
Zurück zum Zitat Pattison DI, Davies MJ (2006) Reactions of myeloperoxidase-derived oxidants with biological substrates: gaining chemical insight into human inflammatory diseases. Curr Med Chem 13:3271–3290PubMedCrossRef Pattison DI, Davies MJ (2006) Reactions of myeloperoxidase-derived oxidants with biological substrates: gaining chemical insight into human inflammatory diseases. Curr Med Chem 13:3271–3290PubMedCrossRef
20.
Zurück zum Zitat Klebanoff SJ (1999) Myeloperoxidase. Proc Assoc Am Physicians 111:383–389PubMed Klebanoff SJ (1999) Myeloperoxidase. Proc Assoc Am Physicians 111:383–389PubMed
21.
Zurück zum Zitat Dally H, Gassner K, Jager B, Schmezer P, Spiegelhalder B, Edler L, Drings P, Dienemann H, Schulz V, Kayser K et al (2002) Myeloperoxidase (MPO) genotype and lung cancer histologic types: the MPO -463 A allele is associated with reduced risk for small cell lung cancer in smokers. Int J Cancer 102:530–535PubMedCrossRef Dally H, Gassner K, Jager B, Schmezer P, Spiegelhalder B, Edler L, Drings P, Dienemann H, Schulz V, Kayser K et al (2002) Myeloperoxidase (MPO) genotype and lung cancer histologic types: the MPO -463 A allele is associated with reduced risk for small cell lung cancer in smokers. Int J Cancer 102:530–535PubMedCrossRef
22.
Zurück zum Zitat Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M, Reynolds WF (1996) An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 271:14412–14420PubMedCrossRef Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M, Reynolds WF (1996) An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 271:14412–14420PubMedCrossRef
23.
Zurück zum Zitat Wu X, Schabath MB, Spitz MR (2003) Myeloperoxidase promoter region polymorphism and lung cancer risk. Methods Mol Med 75:121–133PubMed Wu X, Schabath MB, Spitz MR (2003) Myeloperoxidase promoter region polymorphism and lung cancer risk. Methods Mol Med 75:121–133PubMed
24.
Zurück zum Zitat Feyler A, Voho A, Bouchardy C, Kuokkanen K, Dayer P, Hirvonen A, Benhamou S (2002) Point: myeloperoxidase -463G –> a polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 11:1550–1554PubMed Feyler A, Voho A, Bouchardy C, Kuokkanen K, Dayer P, Hirvonen A, Benhamou S (2002) Point: myeloperoxidase -463G –> a polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 11:1550–1554PubMed
25.
Zurück zum Zitat Matsuo K, Hamajima N, Shinoda M, Hatooka S, Inoue M, Takezaki T, Onda H, Tajima K (2001) Possible risk reduction in esophageal cancer associated with MPO -463 A allele. J Epidemiol 11:109–114PubMed Matsuo K, Hamajima N, Shinoda M, Hatooka S, Inoue M, Takezaki T, Onda H, Tajima K (2001) Possible risk reduction in esophageal cancer associated with MPO -463 A allele. J Epidemiol 11:109–114PubMed
26.
Zurück zum Zitat Hayes JD, McLellan LI (1999) Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Radic Res 31:273–300PubMedCrossRef Hayes JD, McLellan LI (1999) Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Radic Res 31:273–300PubMedCrossRef
27.
Zurück zum Zitat Bosch TM, Meijerman I, Beijnen JH, Schellens JH (2006) Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 45:253–285PubMedCrossRef Bosch TM, Meijerman I, Beijnen JH, Schellens JH (2006) Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 45:253–285PubMedCrossRef
28.
Zurück zum Zitat Gate L, Tew KD (2001) Glutathione S-transferases as emerging therapeutic targets. Expert Opin Ther Targets 5:477–489PubMedCrossRef Gate L, Tew KD (2001) Glutathione S-transferases as emerging therapeutic targets. Expert Opin Ther Targets 5:477–489PubMedCrossRef
29.
Zurück zum Zitat McIlwain CC, Townsend DM, Tew KD (2006) Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 25:1639–1648PubMedCrossRef McIlwain CC, Townsend DM, Tew KD (2006) Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 25:1639–1648PubMedCrossRef
30.
Zurück zum Zitat Pandya U, Srivastava SK, Singhal SS, Pal A, Awasthi S, Zimniak P, Awasthi YC, Singh SV (2000) Activity of allelic variants of Pi class human glutathione S-transferase toward chlorambucil. Biochem Biophys Res Commun 278:258–262PubMedCrossRef Pandya U, Srivastava SK, Singhal SS, Pal A, Awasthi S, Zimniak P, Awasthi YC, Singh SV (2000) Activity of allelic variants of Pi class human glutathione S-transferase toward chlorambucil. Biochem Biophys Res Commun 278:258–262PubMedCrossRef
31.
Zurück zum Zitat Hu X, Xia H, Srivastava SK, Pal A, Awasthi YC, Zimniak P, Singh SV (1998) Catalytic efficiencies of allelic variants of human glutathione S-transferase P1-1 toward carcinogenic anti-diol epoxides of benzo[c]phenanthrene and benzo[g]chrysene. Cancer Res 58:5340–5343PubMed Hu X, Xia H, Srivastava SK, Pal A, Awasthi YC, Zimniak P, Singh SV (1998) Catalytic efficiencies of allelic variants of human glutathione S-transferase P1-1 toward carcinogenic anti-diol epoxides of benzo[c]phenanthrene and benzo[g]chrysene. Cancer Res 58:5340–5343PubMed
32.
Zurück zum Zitat Ishimoto TM, li-Osman F (2002) Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli. Pharmacogenetics 12:543–553PubMedCrossRef Ishimoto TM, li-Osman F (2002) Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli. Pharmacogenetics 12:543–553PubMedCrossRef
33.
Zurück zum Zitat Sweeney C, McClure GY, Fares MY, Stone A, Coles BF, Thompson PA, Korourian S, Hutchins LF, Kadlubar FF, Ambrosone CB (2000) Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res 60:5621–5624PubMed Sweeney C, McClure GY, Fares MY, Stone A, Coles BF, Thompson PA, Korourian S, Hutchins LF, Kadlubar FF, Ambrosone CB (2000) Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res 60:5621–5624PubMed
34.
Zurück zum Zitat Dasgupta RK, Adamson PJ, Davies FE, Rollinson S, Roddam PL, Ashcroft AJ, Dring AM, Fenton JA, Child JA, Allan JM et al (2003) Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood 102:2345–2350PubMedCrossRef Dasgupta RK, Adamson PJ, Davies FE, Rollinson S, Roddam PL, Ashcroft AJ, Dring AM, Fenton JA, Child JA, Allan JM et al (2003) Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood 102:2345–2350PubMedCrossRef
35.
Zurück zum Zitat Lee JM, Wu MT, Lee YC, Yang SY, Chen JS, Hsu HH, Huang PM, Kuo SW, Lee CJ, Chen CJ (2005) Association of GSTP1 polymorphism and survival for esophageal cancer. Clin Cancer Res 11:4749–4753PubMedCrossRef Lee JM, Wu MT, Lee YC, Yang SY, Chen JS, Hsu HH, Huang PM, Kuo SW, Lee CJ, Chen CJ (2005) Association of GSTP1 polymorphism and survival for esophageal cancer. Clin Cancer Res 11:4749–4753PubMedCrossRef
36.
Zurück zum Zitat Bewick MA, Conlon MS, Lafrenie RM (2006) Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer. J Clin Oncol 24:5645–5651PubMedCrossRef Bewick MA, Conlon MS, Lafrenie RM (2006) Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer. J Clin Oncol 24:5645–5651PubMedCrossRef
38.
Zurück zum Zitat Brockstedt U, Krajinovic M, Richer C, Mathonnet G, Sinnett D, Pfau W, Labuda D (2002) Analyses of bulky DNA adduct levels in human breast tissue and genetic polymorphisms of cytochromes P450 (CYPs), myeloperoxidase (MPO), quinone oxidoreductase (NQO1), and glutathione S-transferases (GSTs). Mutat Res 516:41–47PubMed Brockstedt U, Krajinovic M, Richer C, Mathonnet G, Sinnett D, Pfau W, Labuda D (2002) Analyses of bulky DNA adduct levels in human breast tissue and genetic polymorphisms of cytochromes P450 (CYPs), myeloperoxidase (MPO), quinone oxidoreductase (NQO1), and glutathione S-transferases (GSTs). Mutat Res 516:41–47PubMed
39.
Zurück zum Zitat Ambrosone CB, Sweeney C, Coles BF, Thompson PA, McClure GY, Korourian S, Fares MY, Stone A, Kadlubar FF, Hutchins LF (2001) Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res 61:7130–7135PubMed Ambrosone CB, Sweeney C, Coles BF, Thompson PA, McClure GY, Korourian S, Fares MY, Stone A, Kadlubar FF, Hutchins LF (2001) Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res 61:7130–7135PubMed
40.
Zurück zum Zitat Sweeney C, Nazar-Stewart V, Stapleton PL, Eaton DL, Vaughan TL (2003) Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. Cancer Epidemiol Biomarkers Prev 12:527–533PubMed Sweeney C, Nazar-Stewart V, Stapleton PL, Eaton DL, Vaughan TL (2003) Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. Cancer Epidemiol Biomarkers Prev 12:527–533PubMed
41.
Zurück zum Zitat Kim EJ, Jeong P, Quan C, Kim J, Bae SC, Yoon SJ, Kang JW, Lee SC, Jun WJ, Kim WJ (2005) Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Urology 65:70–75PubMedCrossRef Kim EJ, Jeong P, Quan C, Kim J, Bae SC, Yoon SJ, Kang JW, Lee SC, Jun WJ, Kim WJ (2005) Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Urology 65:70–75PubMedCrossRef
42.
Zurück zum Zitat Goekkurt E, Hoehn S, Wolschke C, Wittmer C, Stueber C, Hossfeld DK, Stoehlmacher J (2006) Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)—novel predictors for response and survival in gastric cancer patients. Br J Cancer 94:281–286PubMedCrossRef Goekkurt E, Hoehn S, Wolschke C, Wittmer C, Stueber C, Hossfeld DK, Stoehlmacher J (2006) Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)—novel predictors for response and survival in gastric cancer patients. Br J Cancer 94:281–286PubMedCrossRef
43.
Zurück zum Zitat Gonlugur U, Pinarbasi H, Gonlugur TE, Silig Y (2006) The association between polymorphisms in glutathione S-transferase (GSTM1 and GSTT1) and lung cancer outcome. Cancer Invest 24:497–501PubMedCrossRef Gonlugur U, Pinarbasi H, Gonlugur TE, Silig Y (2006) The association between polymorphisms in glutathione S-transferase (GSTM1 and GSTT1) and lung cancer outcome. Cancer Invest 24:497–501PubMedCrossRef
44.
Zurück zum Zitat Barragan E, Collado M, Cervera J, Martin G, Bolufer P, Roman J, Sanz MA (2006) The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia. Leuk Res 31:947–953PubMedCrossRef Barragan E, Collado M, Cervera J, Martin G, Bolufer P, Roman J, Sanz MA (2006) The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia. Leuk Res 31:947–953PubMedCrossRef
45.
Zurück zum Zitat Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, Lenz HJ (2002) Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94:936–942PubMed Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, Lenz HJ (2002) Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94:936–942PubMed
46.
Zurück zum Zitat Sun XF, Ahmadi A, Arbman G, Wallin A, Asklid D, Zhang H (2005) Polymorphisms in sulfotransferase 1A1 and glutathione S-transferase P1 genes in relation to colorectal cancer risk and patients’ survival. World J Gastroenterol 11:6875–6879PubMed Sun XF, Ahmadi A, Arbman G, Wallin A, Asklid D, Zhang H (2005) Polymorphisms in sulfotransferase 1A1 and glutathione S-transferase P1 genes in relation to colorectal cancer risk and patients’ survival. World J Gastroenterol 11:6875–6879PubMed
47.
Zurück zum Zitat Holley SL, Rajagopal R, Hoban PR, Deakin M, Fawole AS, Elder JB, Elder J, Smith V, Strange RC, Fryer AA (2006) Polymorphisms in the glutathione S-transferase mu cluster are associated with tumour progression and patient outcome in colorectal cancer. Int J Oncol 28:231–236PubMed Holley SL, Rajagopal R, Hoban PR, Deakin M, Fawole AS, Elder JB, Elder J, Smith V, Strange RC, Fryer AA (2006) Polymorphisms in the glutathione S-transferase mu cluster are associated with tumour progression and patient outcome in colorectal cancer. Int J Oncol 28:231–236PubMed
48.
Zurück zum Zitat Goode EL, Dunning AM, Kuschel B, Healey CS, Day NE, Ponder BA, Easton DF, Pharoah PP (2002) Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res 62:3052–3057PubMed Goode EL, Dunning AM, Kuschel B, Healey CS, Day NE, Ponder BA, Easton DF, Pharoah PP (2002) Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res 62:3052–3057PubMed
Metadaten
Titel
Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer
verfasst von
Mary A. Bewick
Michael S. C. Conlon
Robert M. Lafrenie
Publikationsdatum
01.09.2008
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2008
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9764-8

Weitere Artikel der Ausgabe 1/2008

Breast Cancer Research and Treatment 1/2008 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.